More importantly, there were reports that indicated that the upregulation of FOXP4-AS1 showed longer overall survival in ovarian cancer (25, 26), suggesting that it could be an efficacious prognostic biomarker. This evidence concerns the gene FOXP4 and ovarian carcinoma.